Zealand Pharma reports positive data from phase Ib trial
The candidate dapiglutide has been assessed both safe and well tolerated in humans and has several potential indications within gastrointestinal and metabolic diseases, reports Zealand Pharma.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
Zealand Pharma has completed a small phase Ib study with the GLP1-GLP2 dual receptor agonist dapiglutide, it reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
